Daniele, Gennaro

Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials

Di Maio, M., Gallo, C., Leighl, N. B., Piccirillo, M. C., Daniele, G., Nuzzo, F., Gridelli, C., Gebbia, V., Ciardiello, F., De Placido, S., et al. (2015) · Journal of Clinical Oncology

Cancer survivorship and carePharmacovigilance and Adverse Drug Reactions

Cited by 497

Vascular Endothelial Growth Factor Receptor-1 Contributes to Resistance to Anti–Epidermal Growth Factor Receptor Drugs in Human Cancer Cells

Bianco, R., Rosa, R., Damiano, V., Daniele, G., Gelardi, T., Garofalo, S., Tarallo, V., De Falco, S., Melisi, D., Benelli, R., et al. (2008) · Clinical Cancer Research

Angiogenesis and VEGF in CancerHER2/EGFR in Cancer Research

Cited by 149

Sevabertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer

Le, X., Kim, T. M., Loong, H. H., Prelaj, A., Goh, B. C., Li, L., Fang, Y., Lu, S., Dong, X., Wu, L., et al. (2025) · New England Journal of Medicine

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 70

Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: The CAPPA-2 study

Morabito, A., Gebbia, V., Di Maio, M., Cinieri, S., Viganò, M. G., Bianco, R., Barbera, S., Cavanna, L., De Marinis, F., Montesarchio, V., et al. (2013) · Lung Cancer

Lung Cancer Diagnosis and TreatmentLung Cancer Treatments and Mutations

Cited by 53

LBA27 First-in-human results of STX-478, a mutant-selective PI3Ka inhibitor, in advanced solid tumor patients

Montero, A. J., Giordano, A., Jhaveri, K., Munster, P., Rodon, J., Lorusso, P., Orr, D., Bartolomé Arcilla, J., Italiano, A., Elias, A., et al. (2024) · Annals of Oncology

PI3K/AKT/mTOR signaling in cancerAdvanced Breast Cancer Therapies

Cited by 9